AVITA Medical Names Cary Vance as CEO
Key points
- Board appoints Cary Vance as President and CEO
- Jan Stern Reed elected as Chair of the AVITA Board
- Vance to lead AVITA's growth and strategic priorities
Full summary
AVITA Medical, a leading therapeutic acute wound care company, has announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The Board has also appointed Jan Stern Reed as its Chair, effective immediately. Mr. Vance, who has served as Interim CEO since October 2025, will continue to serve on the Board as an executive member. The Board unanimously concluded that Vance is the right leader to serve as CEO on a permanent basis, citing his decisive leadership, stabilization of the business, sharpening of strategic focus, and rebuilding of confidence and enthusiasm with employees, customers, and shareholders. Vance has over 30 years of experience driving value creation and commercializing innovative medical technologies. Jan Stern Reed, the newly appointed Chair, has over 35 years of legal and business management experience in the healthcare industry, both as an executive leader and board member. The company also announced the date for its first quarter 2026 earnings call, which will be held on Thursday, May 14, 2026.
Outlook
The company is focused on scaling adoption, supporting more clinicians in delivering better outcomes, and translating that momentum into consistent performance. The new CEO and Chair will work closely to support AVITA Medical's strategic priorities and continued growth.
Summary generated by a large language model. Please interpret with care.